Abstract

Objective:To determine the efficacy of topical Nepafenac (0.1%), administered post-operatively in prevention of Macular Edema (ME), after cataract surgery in patients with Non-Proliferative Diabetic Retinopathy (NPDR).Methods:This randomized control trial was conducted at Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi from Sep 2015 to Sep 2016. Sixty eyes of 60 patients with NPDR underwent phacoemulsification with intraocular lens implantation. Group 1 received 0.1% Nepafenac, 8-hourly, in operated eye after cataract surgery for three months, along with routine post-operative medications. Group-2 received only routine post-operative medications. ME was defined as increase in Central Macular Thickness (CMT) of >10% from pre-operative baseline, measured using spectral domain optical coherence tomography.Results:Mean age of study population was 60.97±4.91 years. Out of 60 patients, 34 (56.7%) were males and 24 (43.3%) were females. Mean pre-operative CMT, 3 months post-operative CMT, mean change in CMT and mean frequency change in CMT of Group-1 was 226.5±10.86µm, 228.83±14.56 µm, 2.33±10.45 µm and 1.05% respectively. Mean pre-operative CMT, three months post-operative CMT, mean change in CMT and mean frequency change in CMT in Group-2 was 223.93±11.69µm, 236.17±16.16 µm, 12.23±12.40µm and 5.51% respectively. ME was observed in one patient (3.3%) in Group-1, and seven patients (23.3%) in Group 2. The difference of mean change in CMT and frequency change in CMT between groups was statistically significant (p<0.05).Conclusion:0.1% topical Nepafenac is effective in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy (NPDR).

Highlights

  • Diabetes Mellitus (DM) has potentially blinding effects on human eye

  • Our objective was to determine the efficacy of topical Nepafenac (0.1%), administered postoperatively in prevention of Macular Edema (ME), after cataract surgery in patients with NonProliferative Diabetic Retinopathy (NPDR)

  • Comparison of post-operative Central Macular Thickness (CMT) from pre-operative value within each group is given in Table-II

Read more

Summary

INTRODUCTION

Diabetes Mellitus (DM) has potentially blinding effects on human eye. There is strong evidence of role of diabetes in pathogenesis of age-related cataracts. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) cause Cyclo–Oxygenase enzyme inhibition and thereby inhibit the production of prostaglandins.[5] Nepafenac is a prodrug, which is hydrolysed in the intraocular tissues to Amfenac. This active substance has good efficacy, excellent bioavailability and minimum toxic effects on ocular tissues.[6] Inhibition of prostaglandins synthesis by Nepafenac prevents development of ME.[7]. Our objective was to determine the efficacy of topical Nepafenac (0.1%), administered postoperatively in prevention of Macular Edema (ME), after cataract surgery in patients with NonProliferative Diabetic Retinopathy (NPDR)

METHODS
DISCUSSION
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call